Following a survey of 100 executives at the top 20 pharmaceutical companies, Rafael Natanek, a partner with Bain & Company, talked to S&P Global Market Intelligence about the critical importance of a successful new drug launch, given that drug companies will derive 25% to 80% of their revenue from

“The German [banking] market continues to be very difficult in comparison to many European countries,” said Dirk Vater, a partner with Bain & Company. “Margins are thin thanks to strong competition, fragmentation and very price sensitive retail clients.”